Charles River
Why Robinhood?
Robinhood gives you the tools you need to put your money in motion. You can buy or sell Charles River and other ETFs, options, and stocks.About CRL
Charles River Laboratories International, Inc. engages in providing products and services to help pharmaceutical and biotechnology companies. It operates through the following segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions.
CRL Key Statistics
Stock Snapshot
As of today, Charles River(CRL) shares are valued at $219.70. The company's market cap stands at 10.81B, with a P/E ratio of -141.29.
On 2026-01-19, Charles River(CRL) stock moved within a range of $218.98 to $227.51. With shares now at $219.70, the stock is trading +0.3% above its intraday low and -3.4% below the session's peak.
Trading activity shows a volume of 770.87K, compared to an average daily volume of 870.55K.
The stock's 52-week range extends from a low of $91.86 to a high of $228.88.
The stock's 52-week range extends from a low of $91.86 to a high of $228.88.
CRL News
In January 2026, Charles River Laboratories announced a planned CEO transition to long-time executive Birgit Girshick, expanded its M&A pipeline, including deal...
Citi analyst Patrick Donnelly raised the firm’s price target on Charles River (CRL) to $265 from $200 and keeps a Buy rating on the shares. The firm adjusted ta...
Claim 70% Off TipRanks Premium The latest announcement is out from Charles River Labs ( (CRL) ). At the J.P. Morgan Conference, Charles River Laboratories rep...
Analyst ratings
55%
of 20 ratingsMore CRL News
Charles River Laboratories International (CRL) has announced a major leadership transition, with long-time CEO James C. Foster scheduled to retire in May 2026 a...
(RTTNews) - Charles River Laboratories International Inc. (CRL) unveiled a series of strategic moves at the J.P. Morgan 44th Annual Healthcare Conference, inclu...
The company states: “Charles River (CRL) announced two planned acquisitions of K.F. (Cambodia) Ltd. and PathoQuest SAS; the addition of Dr. Namandje N. Bumpus a...